IPO registrations (S-1, F-1) · Registrants
Lyra Therapeutics, Inc.
- SEC CIK
- 1327273 · filings on EDGAR ↗
- Former names
- 480 Biomedical, Inc. (2012–2016); Arsenal Vascular, Inc. (2011–2011); Arsenal Medical, Inc. (2009–2010); WMR Biomedical Inc (2005–2009)
- Registration
- Form S-1, first filed 2020-03-06, last 2025-07-22; 2 initial registrations, 1 amendment
- Outcome
- Final prospectus filed 2020-05-01; declared effective 2020-04-30
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus 3841
- Incorporated in
- DE
- Business address
- 480 ARSENAL WAY, Watertown, MA 02472
- EDGAR entity type
- operating
- Insiders and CEO pay
- Lyra Therapeutics, Inc. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2020-04-27)
- Final price
- $16.00 per share, within the range (424B4 filed 2020-05-01, an initial public offering)
- Shares sold
- 3,500,000
- Gross proceeds
- $56,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol LYRA
- Lead underwriters
- BofA Securities; Jefferies (1,225,000 shares); William Blair (525,000 shares)
- Syndicate
- BTIG (350,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Federal award recipient: LYRA THERAPEUTICS INC Fuzzy (name and state)
- Form D issuer: Lyra Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: Lyra Therapeutics, Inc. EXACT (CIK (EXACT))
- Person page: Jonathan A Flint Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
- Person page: R Don Elsey Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
- Person page: Richard A D'Amore Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
Filings 13
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-03-06 | S-1 | S-1 (registration) | Lyra Therapeutics, Inc. | 0001193125-20-065213 ↗ |
| 2020-04-27 | S-1/A | S-1/A (amendment) | Lyra Therapeutics, Inc. | 0001193125-20-120337 ↗ |
| 2020-04-30 | EFFECT | EFFECT (declared effective) | Lyra Therapeutics, Inc. | 9999999995-20-000931 ↗ |
| 2020-05-01 | 424B4 | 424B4 (final prospectus) | Lyra Therapeutics, Inc. | 0001193125-20-131089 ↗ |
| 2021-05-20 | EFFECT | EFFECT (declared effective) | Lyra Therapeutics, Inc. | 9999999995-21-002044 ↗ |
| 2022-05-20 | EFFECT | EFFECT (declared effective) | Lyra Therapeutics, Inc. | 9999999995-22-001554 ↗ |
| 2023-07-07 | EFFECT | EFFECT (declared effective) | Lyra Therapeutics, Inc. | 9999999995-23-002032 ↗ |
| 2024-04-01 | EFFECT | EFFECT (declared effective) | Lyra Therapeutics, Inc. | 9999999995-24-000816 ↗ |
| 2025-07-22 | S-1 | S-1 (registration) | Lyra Therapeutics, Inc. | 0001193125-25-162669 ↗ |
| 2025-07-30 | EFFECT | EFFECT (declared effective) | Lyra Therapeutics, Inc. | 9999999995-25-002415 ↗ |
| 2026-03-26 | EFFECT | EFFECT (declared effective) | Lyra Therapeutics, Inc. | 9999999995-26-000934 ↗ |
| 2026-03-26 | EFFECT | EFFECT (declared effective) | Lyra Therapeutics, Inc. | 9999999995-26-000936 ↗ |
| 2026-03-26 | EFFECT | EFFECT (declared effective) | Lyra Therapeutics, Inc. | 9999999995-26-000939 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-04-27 | S-1/A | registration statement | $14.00–$16.00 | 3,500,000 | - | Nasdaq LYRA | 4 | primary document; range, price sentence, shares headline, proceeds computed, price outside the range dropped, cover names 4 | document ↗ | |
| 2020-05-01 | 424B4 | final prospectus | $16.00 | 3,500,000 | $56,000,000 | Nasdaq LYRA | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ALTMAN MICHAEL SETH | Director | 6 | 2020–2024 | ||
| ANDERSON EDWARD T | Director; Director,TenPercentOwner | 8 | 2020–2023 | ||
| DAMORE RICHARD A | TenPercentOwner | 4 | 2020–2023 | person page Fuzzy | |
| EDELMAN JOSEPH | Director,TenPercentOwner; TenPercentOwner | 8 | 2020–2025 | ||
| Edgerly-Pflug Laura | Officer | See Remarks | 2 | 2020 | |
| Elsey R Don | Officer | CFO, Treasurer & Secretary | 3 | 2020–2021 | person page Fuzzy |
| Flint Jonathan A | TenPercentOwner | 2 | 2020 | person page Fuzzy | |
| LANGER ROBERT | Director | 3 | 2020 | ||
| MCGUIRE TERRANCE | TenPercentOwner | 2 | 2020 | ||
| MERRIFIELD C ANN | Director | 9 | 2020–2025 | ||
| MOTT RICHARD W | TenPercentOwner | 1 | 2020 | ||
| NBVM GP, LLC | TenPercentOwner | 4 | 2020–2023 | ||
| North Bridge Venture Management VI, L.P. | TenPercentOwner | 4 | 2020–2023 | ||
| North Bridge Venture Management V, L.P. | TenPercentOwner | 4 | 2020–2023 | ||
| NORTH BRIDGE VENTURE PARTNERS V A LP | TenPercentOwner | 4 | 2020–2023 | ||
| NORTH BRIDGE VENTURE PARTNERS V-B LP | TenPercentOwner | 4 | 2020–2023 | ||
| North Bridge Venture Partners VI L P | TenPercentOwner | 4 | 2020–2023 | ||
| Noyes Corinne | Officer | See Remarks | 5 | 2020–2023 | |
| Palasis Maria | Director,Officer | President & CEO; Principal Executive Officer | 17 | 2020–2026 | |
| PERCEPTIVE ADVISORS LLC | Director,TenPercentOwner; TenPercentOwner | 8 | 2020–2025 | ||
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | TenPercentOwner | 7 | 2020–2025 | ||
| Perceptive LS (A), LLC | TenPercentOwner | 7 | 2020–2025 | ||
| Polaris Venture Management Co IV LLC | TenPercentOwner | 2 | 2020 | ||
| Polaris Venture Management Co. V, L.L.C. | TenPercentOwner | 2 | 2020 | ||
| POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV LP | TenPercentOwner | 2 | 2020 | ||
| Polaris Venture Partners Entrepreneurs' Fund V, L.P. | TenPercentOwner | 2 | 2020 | ||
| Polaris Venture Partners Founders' Fund V, L.P. | TenPercentOwner | 2 | 2020 | ||
| POLARIS VENTURE PARTNERS IV LP | TenPercentOwner | 2 | 2020 | ||
| Polaris Venture Partners Special Founders' Fund V, L.P. | TenPercentOwner | 2 | 2020 | ||
| Polaris Venture Partners V, L.P. | TenPercentOwner | 2 | 2020 | ||
| Poukalov Konstantin | Director | 6 | 2020–2024 | ||
| Roberts Carmichael | TenPercentOwner | 2 | 2020 | ||
| Smith W Bradford | Director | 7 | 2020–2026 | ||
| WHITESIDES GEORGE M | Director | 3 | 2020 | ||
| Levy Guy | TenPercentOwner | 2 | 2020 | ||
| Soleus Capital Group, LLC | TenPercentOwner | 1 | 2020 | ||
| Soleus Capital, LLC | TenPercentOwner | 1 | 2020 | ||
| Soleus Capital Master Fund, L.P. | TenPercentOwner | 1 | 2020 | ||
| Soleus PE GP I, LLC | TenPercentOwner | 2 | 2020 | ||
| Soleus Private Equity Fund I, L.P. | TenPercentOwner | 2 | 2020 | ||
| Soleus Private Equity GP I, LLC | TenPercentOwner | 2 | 2020 | ||
| Richard Robert E. | Officer | SVP of R&D; SVP, Technical Operations | 5 | 2020–2023 | |
| Nelson Pamela E. | Officer | Senior VP, Regulatory Affairs; SVP, Regulatory Affairs | 4 | 2020–2022 | |
| snyderman nancy lynn MD | Director | 8 | 2020–2025 | ||
| Cavalier Jason | Officer | Chief Financial Officer; Principal Financial Officer | 10 | 2021–2026 | |
| Waksal Harlan | Director,Officer | Executive Chair | 8 | 2022–2024 | |
| TOBIN JAMES R | Director | 5 | 2022–2025 | ||
| Nieman Richard | Officer | Chief Medical Officer | 4 | 2022–2024 | |
| Bishop John E | Officer | Chief Technology Officer | 3 | 2023–2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2023-06-09 | Lyra Therapeutics, Inc. | Biotechnology | $50,000,008 | $50,000,008 | 24 | 1 |
| 2022-04-26 | Lyra Therapeutics, Inc. | Biotechnology | $100,494,970 | $100,494,970 | 34 | 1 |
| 2020-01-27 | Lyra Therapeutics, Inc. | Other | $28,049,999 | $28,049,999 | 14 | 1 |
| 2016-11-28 | 480 Biomedical, Inc. | Other | $5,999,999 | $5,999,999 | 9 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | LYRA THERAPEUTICS, INC. | MA | Form 5500 (employee benefit plans) | name and state |
| Federal award recipient | LYRA THERAPEUTICS INC | MA | Federal spending (USAspending) | name and state |
| Form D issuer | Lyra Therapeutics, Inc. | MA | Form D private offerings | CIK (EXACT) |
| IPO registrant | TETRAPHASE PHARMACEUTICALS INC | MA | IPO registrations (S-1, F-1) | same street address and ZIP code, 480 ARSENAL WAY 02472 (FUZZY: a shared address, not proof of a shared organization) |
| Patent assignee | LYRA THERAPEUTICS, INC. | MA | Patents (USPTO) | name and state |
| SEC filer | Lyra Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | LYRA THERAPEUTICS, INC. | MA | Trademarks (USPTO) | name and state |
| Person page | Jonathan A Flint | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) | |
| Person page | R Don Elsey | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) | |
| Person page | Richard A D'Amore | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Surgical & Medical Instruments & Apparatus, MA first:
- NMT MEDICAL INC MA
- ARBIOS SYSTEMS INC MA
- INSULET CORP MA
- LEMAITRE VASCULAR INC MA
- BIOVENTRIX, INC. MA
- NeuroMetrix, Inc. MA
- INVIVO THERAPEUTICS HOLDINGS CORP. MA
- ACCELLENT LLC MA
- T2 Biosystems, Inc. MA
- Corindus Vascular Robotics, Inc. MA
In other datasets, the same topic (Technology) in MA:
- Form D issuer: 10 Percent Happier, Inc. (Form D private offerings)
- Lobbying client: 5G ACTION NOW (Federal lobbying (LDA))
Interests: Surgical & Medical Instruments & Apparatus · Technology